Dulaglutide (Trulicity): The third once-weekly GLP-1 agonist

P and T

Volumn 41, Issue 6, 2016, Pages 357-360

  Smith, Lillian L ^a   Mosley, Juan F ^a   Parke, Crystal ^a   Brown, Jamal ^a   Barris, Lillian S ^a   Phan, Linh D ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DULAGLUTIDE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN;

ABDOMINAL PAIN; ABSORPTION RATE CONSTANT; ACCUMULATION INDEX; AGE; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DYSPEPSIA; FATIGUE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; GENDER; GLOMERULUS FILTRATION RATE; GLUCAGON RELEASE; GLYCEMIC CONTROL; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN RELEASE; LOSS OF APPETITE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; QT PROLONGATION; RETINOPATHY; SINGLE DRUG DOSE; STEADY STATE; STOMACH EMPTYING; STOMACH MOTILITY; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION;

EID: 84973334731     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 Atlanta, Georgia: U.S. Department of Health and Human Services. 2014;
2. Khardori R. Type 2 diabetes mellitus medication. Medscape October 82015;Available at: http://emedicine.medscape.com/article/117853-medication. Accessed May 18, 2016.
3. Dungan K, Buse J. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide. Clin Diabetes 2005;23;(2):56-62.Available at: http://clinical.diabetesjournals.org/content/23/2/56.full. Accessed February 10, 2015.
4. Garber A. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. 2011;34;(suppl 2):S279-S284.10.2337/dc11-s231
5. Trulicity (dulaglutide) prescribing information Indianapolis, Indiana: Eli Lilly and Company. 2014;
6. Grunberger G, Chang A, Soria GG, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012;29;(10):1260-1267.10.1111/j.1464-5491.2012.03745.x
7. RxList. Trulicity clinical pharmacology. November 102014;Available at: www.rxlist.com/trulicity-drug/clinical-pharmacology.htm. Accessed February 9, 2015.
8. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014;37;(8):2159-2167.10.2337/dc13-2760
9. Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014;37;(8):2168-2176.10.2337/dc13-2759
10. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37;(8):2149-2158.10.2337/dc13-2761
11. Red Book Online Ann Arbor, Michigan: Truven Health Analytics. Accessed May 17, 2016.
12. Schwartz S, DeFronzo R. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? The time has come for GLP-1 receptor agonists!. Diabetes Care 2013;36;(7):2107-2111.10.2337/dc12-2060
13. Farrokhi F, Smiley D, Umpierrez G. Glycemic control in non-diabetic critically ill patients. Best Pract Res Clin Endocrinol Metab 2011;25;(5):813-824.
14. DiaTribe. Lilly’s GLP-1 agonist Trulicity shows promising results in trials. July 202014;Available at: http://diatribe.org/drugdevice-name/dulaglutide. Accessed February 9, 2015.
15. Edwards KL, Minze MG. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evid 2015;10:11-21.10.2147/CE.S55944